Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PJ021
- Development stage
- Unknown
- Lead developer
- Chongqing Peg-Bio Biopharm
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Subcutaneous
01
Overview
PJ021 is a recombinant insulin icodec biosimilar being developed by Chongqing Peg-Bio Biopharm for the treatment of type 2 diabetes mellitus. Designed as a long-acting basal insulin analogue for once-weekly subcutaneous administration, PJ021 acts as an agonist of the insulin receptor, mimicking endogenous insulin to regulate glucose metabolism, promote glucose uptake in peripheral tissues, and suppress hepatic glucose production. PJ021 is currently in Phase I clinical development in China.
- Other names
- PJ021 InjectionPJ-021 InjectionPJ 021 InjectionPJ021注射液insulin icodec biosimilar
02
Targets
INSR (Insulin receptor)
Beyond the preview
Go deeper on PJ021.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PJ021.